Literature DB >> 32926319

Clinical features and the traditional Chinese medicine therapeutic characteristics of 293 COVID-19 inpatient cases.

Zixin Shu1, Yana Zhou2, Kai Chang1, Jifen Liu2, Xiaojun Min2, Qing Zhang2, Jing Sun2, Yajuan Xiong2, Qunsheng Zou1, Qiguang Zheng1, Jinghui Ji1, Josiah Poon3,4, Baoyan Liu5, Xuezhong Zhou6, Xiaodong Li7,8.   

Abstract

Coronavirus disease 2019 (COVID-19) is now pandemic worldwide and has heavily overloaded hospitals in Wuhan City, China during the time between late January and February. We reported the clinical features and therapeutic characteristics of moderate COVID-19 cases in Wuhan that were treated via the integration of traditional Chinese medicine (TCM) and Western medicine. We collected electronic medical record (EMR) data, which included the full clinical profiles of patients, from a designated TCM hospital in Wuhan. The structured data of symptoms and drugs from admission notes were obtained through an information extraction process. Other key clinical entities were also confirmed and normalized to obtain information on the diagnosis, clinical treatments, laboratory tests, and outcomes of the patients. A total of 293 COVID-19 inpatient cases, including 207 moderate and 86 (29.3%) severe cases, were included in our research. Among these cases, 238 were discharged, 31 were transferred, and 24 (all severe cases) died in the hospital. Our COVID-19 cases involved elderly patients with advanced ages (57 years on average) and high comorbidity rates (61%). Our results reconfirmed several well-recognized risk factors, such as age, gender (male), and comorbidities, as well as provided novel laboratory indications (e.g., cholesterol) and TCM-specific phenotype markers (e.g., dull tongue) that were relevant to COVID-19 infections and prognosis. In addition to antiviral/antibiotics and standard supportive therapies, TCM herbal prescriptions incorporating 290 distinct herbs were used in 273 (93%) cases. The cases that received TCM treatment had lower death rates than those that did not receive TCM treatment (17/273 = 6.2% vs. 7/20= 35%, P = 0.0004 for all cases; 17/77= 22% vs. 7/9= 77.7%, P = 0.002 for severe cases). The TCM herbal prescriptions used for the treatment of COVID-19 infections mainly consisted of Pericarpium Citri Reticulatae, Radix Scutellariae, Rhizoma Pinellia, and their combinations, which reflected the practical TCM principles (e.g., clearing heat and dampening phlegm). Lastly, 59% of the patients received treatment, including antiviral, antibiotics, and Chinese patent medicine, before admission. This situation might have some effects on symptoms, such as fever and dry cough. By using EMR data, we described the clinical features and therapeutic characteristics of 293 COVID-19 cases treated via the integration of TCM herbal prescriptions and Western medicine. Clinical manifestations and treatments before admission and in the hospital were investigated. Our results preliminarily showed the potential effectiveness of TCM herbal prescriptions and their regularities in COVID-19 treatment.

Entities:  

Keywords:  COVID-19; clinical features; traditional Chinese medicine

Mesh:

Substances:

Year:  2020        PMID: 32926319      PMCID: PMC7488634          DOI: 10.1007/s11684-020-0803-8

Source DB:  PubMed          Journal:  Front Med        ISSN: 2095-0217            Impact factor:   4.592


  28 in total

Review 1.  COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease.

Authors:  Kam Wa Chan; Vivian Taam Wong; Sydney Chi Wai Tang
Journal:  Am J Chin Med       Date:  2020-03-13       Impact factor: 4.667

2.  [Association rules analysis for exploring combined medication characteristics of Fufang Kushen injection: real-world study based on 49 597 cases].

Authors:  Yin Zhang; Yan-Ming Xie; Yan-Nan Li; Chang Zhang; Cen Chen; Yan Zhuang
Journal:  Zhongguo Zhong Yao Za Zhi       Date:  2017-08

3.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

Authors:  Dawei Wang; Bo Hu; Chang Hu; Fangfang Zhu; Xing Liu; Jing Zhang; Binbin Wang; Hui Xiang; Zhenshun Cheng; Yong Xiong; Yan Zhao; Yirong Li; Xinghuan Wang; Zhiyong Peng
Journal:  JAMA       Date:  2020-03-17       Impact factor: 56.272

4.  Current Drugs with Potential for Treatment of COVID-19: A Literature Review.

Authors: 
Journal:  J Pharm Pharm Sci       Date:  2020       Impact factor: 2.327

Review 5.  Network medicine: a network-based approach to human disease.

Authors:  Albert-László Barabási; Natali Gulbahce; Joseph Loscalzo
Journal:  Nat Rev Genet       Date:  2011-01       Impact factor: 53.242

Review 6.  Cholesterol-binding viral proteins in virus entry and morphogenesis.

Authors:  Cornelia Schroeder
Journal:  Subcell Biochem       Date:  2010

7.  Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19).

Authors:  Fang Jiang; Liehua Deng; Liangqing Zhang; Yin Cai; Chi Wai Cheung; Zhengyuan Xia
Journal:  J Gen Intern Med       Date:  2020-03-04       Impact factor: 5.128

8.  A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster.

Authors:  Jasper Fuk-Woo Chan; Shuofeng Yuan; Kin-Hang Kok; Kelvin Kai-Wang To; Hin Chu; Jin Yang; Fanfan Xing; Jieling Liu; Cyril Chik-Yan Yip; Rosana Wing-Shan Poon; Hoi-Wah Tsoi; Simon Kam-Fai Lo; Kwok-Hung Chan; Vincent Kwok-Man Poon; Wan-Mui Chan; Jonathan Daniel Ip; Jian-Piao Cai; Vincent Chi-Chung Cheng; Honglin Chen; Christopher Kim-Ming Hui; Kwok-Yung Yuen
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

9.  Identification of natural compounds with antiviral activities against SARS-associated coronavirus.

Authors:  Shi-You Li; Cong Chen; Hai-Qing Zhang; Hai-Yan Guo; Hui Wang; Lin Wang; Xiang Zhang; Shi-Neng Hua; Jun Yu; Pei-Gen Xiao; Rong-Song Li; Xuehai Tan
Journal:  Antiviral Res       Date:  2005-07       Impact factor: 5.970

10.  Prediction of Molecular Mechanisms for LianXia NingXin Formula: A Network Pharmacology Study.

Authors:  Yang Yang; Kuo Yang; Teng Hao; Guodong Zhu; Ruby Ling; Xuezhong Zhou; Ping Li
Journal:  Front Physiol       Date:  2018-05-08       Impact factor: 4.566

View more
  15 in total

1.  Microbial Characteristics of Common Tongue Coatings in Patients with Precancerous Lesions of the Upper Gastrointestinal Tract.

Authors:  Xiaoyu Kang; Bin Lu; Pan Xiao; Zhaolai Hua; Rui Shen; Jianping Wu; Juan Wu; Zhenfeng Wu; Chun Cheng; Junfeng Zhang
Journal:  J Healthc Eng       Date:  2022-04-18       Impact factor: 3.822

2.  Chinese herbal medicine: Fighting SARS-CoV-2 infection on all fronts.

Authors:  Zhonglei Wang; Liyan Yang
Journal:  J Ethnopharmacol       Date:  2021-01-21       Impact factor: 5.195

Review 3.  Severe Acute Respiratory Syndrome Coronavirus-2 Induces Cytokine Storm and Inflammation During Coronavirus Disease 19: Perspectives and Possible Therapeutic Approaches.

Authors:  Federica Mannino; Alessandra Bitto; Natasha Irrera
Journal:  Front Pharmacol       Date:  2020-11-26       Impact factor: 5.810

Review 4.  Newly Reported Studies on the Increase in Gastrointestinal Symptom Prevalence withCOVID-19 Infection: A Comprehensive Systematic Review and Meta-Analysis.

Authors:  Hakan Akin; Ramazan Kurt; Fatih Tufan; Ahmed Swi; Resat Ozaras; Veysel Tahan; Ghassan Hammoud
Journal:  Diseases       Date:  2020-11-10

5.  Pathophysiology and Management of Tongue Involvement in COVID-19 Patients.

Authors:  Zeinab Mohseni Afshar; Mohammad Barary; Soheil Ebrahimpour; Alireza Janbakhsh; Mandana Afsharian; Amirhossein Hasanpour; Arefeh Babazadeh
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2022-01-06

6.  COVID-19 Transcriptomic Atlas: A Comprehensive Analysis of COVID-19 Related Transcriptomics Datasets.

Authors:  Fatma Alqutami; Abiola Senok; Mahmood Hachim
Journal:  Front Genet       Date:  2021-12-22       Impact factor: 4.599

7.  Using the Symptom Patient Similarity Network to Explore the Difference between the Chinese and Western Medicine Pathways of Ischemic Stroke and its Comorbidities.

Authors:  Lunzhong Zhang; Shu Han; Manli Zhao; Runshun Zhang; Xuebin Zhang; Jing Zhang; Xiaoqing Liu; Yuyao He; Zhao He; Yunfang Dong; Xiaoying Hou; Zijun Mou; Liyun He; Hong Zhou; Jie Yang; Xingyan Huang; Yanjie Hu; Yuefeng Zhang; Lili Zhang; Zhengguang Chen; Xiaozhen Li; Yan Tan; Kegang Cao; Wei Meng; Liqun Zhong
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-01       Impact factor: 2.629

Review 8.  Therapeutic antibodies under development for SARS-CoV-2.

Authors:  Zetong Ma; MengMei Zhu; Shuyi Zhang; Kewen Qian; Chuqi Wang; Wenyan Fu; Changhai Lei; Shi Hu
Journal:  View (Beijing)       Date:  2021-07-12

9.  Prevalence of comorbidity in Chinese patients with COVID-19: systematic review and meta-analysis of risk factors.

Authors:  Tingxuan Yin; Yuanjun Li; Ying Ying; Zhijun Luo
Journal:  BMC Infect Dis       Date:  2021-02-22       Impact factor: 3.090

10.  Predicting Coupled Herbs for the Treatment of Hypertension Complicated with Coronary Heart Disease in Real-World Data Based on a Complex Network and Machine Learning.

Authors:  Jia-Ming Huan; Yun-Lun Li; Xin Zhang; Jian-Liang Wei; Wei Peng; Yi-Min Wang; Xiao-Yi Su; Yi-Fei Wang; Wen-Ge Su
Journal:  Evid Based Complement Alternat Med       Date:  2022-01-22       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.